Despite its benefits, HLA typing in cancer faces several challenges. One of the primary challenges is the genetic diversity of HLA genes, which makes it difficult to find exact matches for transplants. Additionally, the complexity of the immune response in cancer patients can complicate the interpretation of HLA typing results. There are also logistical and financial barriers, as advanced HLA typing techniques can be costly and may not be readily available in all healthcare settings.
